63 episodes

16 Minutes on the News is a short news podcast where we cover the top headlines of the week, the a16z podcast way -- why are these topics in the news; what's real, what's hype from our vantage point; and what are our experts' quick takes on these trends?

About the a16z Podcast: Discusses tech and culture trends, news, and the future -- especially as ‘software eats the world’. It features industry experts, business leaders, and other interesting thinkers and voices from around the world. This podcast is produced by Andreessen Horowitz (aka “a16z”), a Silicon Valley-based venture capital firm. Multiple episodes -- and now shows -- are released every week; visit a16z.com for more details and to sign up for our newsletters and other content as well!

16 Minutes News by a16z Andreessen Horowitz

    • Technology
    • 4.6 • 92 Ratings

16 Minutes on the News is a short news podcast where we cover the top headlines of the week, the a16z podcast way -- why are these topics in the news; what's real, what's hype from our vantage point; and what are our experts' quick takes on these trends?

About the a16z Podcast: Discusses tech and culture trends, news, and the future -- especially as ‘software eats the world’. It features industry experts, business leaders, and other interesting thinkers and voices from around the world. This podcast is produced by Andreessen Horowitz (aka “a16z”), a Silicon Valley-based venture capital firm. Multiple episodes -- and now shows -- are released every week; visit a16z.com for more details and to sign up for our newsletters and other content as well!

    Malaria Vaccine Breakthrough, Beyond the Buzz

    Malaria Vaccine Breakthrough, Beyond the Buzz

    with @jorgecondebio @rvenkayya @smc90

    In this special 2x explainer episode, we dig into what's hype/ what's real about news of a breakthrough malaria vaccine candidate, beyond the headlines and beyond the buzz: data, science, tech, innovation.

    • 36 min
    Apple Event: Desktop-Tablet Convergence, Cord-Cutting, "Find Anything," & More

    Apple Event: Desktop-Tablet Convergence, Cord-Cutting, "Find Anything," & More

    In this week’s episode of 16 Minutes, our show where we cover tech trends in the news — and also cover themes from company developer and innovation events! — we focus on the latest coming out of Apple’s event this week. The company announced a bunch of things, ranging from new device colors and form factors to podcast services, but in this episode we asked regular guest Steven Sinofsky (an a16z board partner and former Microsoft Windows president who has appeared on past event episodes including covering CES and Apple’s M1 chip) to weigh in. He shares what he thinks all these moves say about the evergreen “consumer vs. professional” question, to what the company’s new devices (namely tablets, personal computers, and TVs) tell us about the long arc of innovation.

    ###

    The views expressed here are those of the individual AH Capital Management, L.L.C. (“a16z”) personnel quoted and are not the views of a16z or its affiliates. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. In addition, this content may include third-party advertisements; a16z has not reviewed such advertisements and does not endorse any advertising content contained therein.

    This content is provided for informational purposes only, and should not be relied upon as legal, business, investment, or tax advice. You should consult your own advisers as to those matters. References to any securities or digital assets are for illustrative purposes only, and do not constitute an investment recommendation or offer to provide investment advisory services. Furthermore, this content is not directed at nor intended for use by any investors or prospective investors, and may not under any circumstances be relied upon when making a decision to invest in any fund managed by a16z. (An offering to invest in an a16z fund will be made only by the private placement memorandum, subscription agreement, and other relevant documentation of any such fund and should be read in their entirety.) Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z, and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by Andreessen Horowitz (excluding investments for which the issuer has not provided permission for a16z to disclose publicly as well as unannounced investments in publicly traded digital assets) is available at https://a16z.com/investments/.

    Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Please see https://a16z.com/disclosures for additional important information.

    • 13 min
    J&J Vaccine Pause; FBI Accesses Servers in Exchange Hack

    J&J Vaccine Pause; FBI Accesses Servers in Exchange Hack

    We have two brief segments in today’s episode: News and analysis of the Johnson & Johnson COVID vaccine pause, and the widespread hack of Microsoft Exchange Servers across the country (and the dramatic and unusual steps the FBI took in response).

    Johnson & Johnson: Federal health officials last week revealed that six women who received the vaccine had developed rare and severe blood clots in their brain, in one case fatally. Even more recently, a panel of expert advisors to the Centers for Disease Control determined that they needed more time to assess the risk of the drug, which was approved by the FDA under Emergency Use Authorization, or EUA.

    Our experts are General Partner Jorge Conde, who previously appeared on a episode on J&J efficacy rates, and General Partner Vineeta Agarwala, who is also a practicing clinician at Stanford Hospital, and recently joined us on "16 Minutes" with Dr. Bob Wachter of UCSF to analyze the vaccine rollout in the U.S. They address the clinical facts about the six J&J cases (and contrast it to the social media conversations and headlines), the incidence rate, and what the J&J vaccine shares with the Astra Zeneca vaccine, which has been halted or limited in Europe and elsewhere over similar blood clot concerns.

    FBI and Microsoft Exchange Servers: The Department of Justice recently announced that the FBI, after getting court authorization, had removed malicious code from hundreds of computers running on-premises versions of Microsoft Exchange Server software used to provide email services. In March, Microsoft had announced the initial hack and released detection tools and patches to help owners of the compromised computers, but the latest government announcement revealed that the FBI had taken the step of removing the malicious code, in this case web shells that enable remote administration, from computers that had not mitigated the risk. Microsoft has associated the hackers with state-sponsored actors in China.

    Our expert is a16z's Joel de la Garza, who explains what’s behind this unusual action and figure out where it fits into larger trends of enterprise security and even national security.

    ###

    The views expressed here are those of the individual AH Capital Management, L.L.C. (“a16z”) personnel quoted and are not the views of a16z or its affiliates. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. In addition, this content may include third-party advertisements; a16z has not reviewed such advertisements and does not endorse any advertising content contained therein.

    This content is provided for informational purposes only, and should not be relied upon as legal, business, investment, or tax advice. You should consult your own advisers as to those matters. References to any securities or digital assets are for illustrative purposes only, and do not constitute an investment recommendation or offer to provide investment advisory services. Furthermore, this content is not directed at nor intended for use by any investors or prospective investors, and may not under any circumstances be relied upon when making a decision to invest in any fund managed by a16z. (An offering to invest in an a16z fund will be made only by the private placement memorandum, subscription agreement, and other relevant documentation of any such fund and should be read in their entirety.) Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z, and there can be no assurance that the investments will be profit

    • 15 min
    NFTs: What, Where, How, Why, Who

    NFTs: What, Where, How, Why, Who

    with @ljxie @jessewldn @smc90

    This deep-dive (one of our 3-4X explainer episodes here) teases apart what's hype/ what's real and the what, where, how, why, who -- answering questions top of mind around all things NFTs.

    • 56 min
    The U.S. Vaccine Rollout

    The U.S. Vaccine Rollout

    Today on our news analysis show 16 Minutes — since this show is all about teasing apart what’s hype/ what’s real and where we are on the long arc of innovation — we're taking a quick pulse-check with the experts on just where we are with the COVID vaccine rollout in the U.S. 

    Our experts today are Dr. Bob Wachter, the Chair of the Department of Medicine at UCSF — he has come to additional prominence during the pandemic as a regular public resource, providing daily updates & reports on Twitter throughout the crisis. He’s also currently guest-hosting the “In the Bubble” podcast. We also have Dr. Vineeta Agarwala, a general partner in a16z bio who is also a practicing clinician at Stanford Hospital. 

    You can catch our ongoing coverage of all things vaccines at a16z.com/vaccines.

    But in this episode we cover where we really are right now with the vaccine rollout — is it working or not, given all the buzz and mixed messages we’ve been hearing on social and in the media? We cover everything from distribution, in practice (that is, from the clinical/ on-the-ground perspective); to other dynamics (such as new strains), to demand for the vaccines (including vaccine hesitancy, and it's not just about anti-vaxxers); to the data (which is where we start). On Friday the CDC reported that about 77 million people in the U.S. have currently received at least one dose of a COVID vaccine, with about 42 million who have been fully vaccinated. 

    • 18 min
    The Johnson & Johnson Vaccine and COVID Efficacy Rates

    The Johnson & Johnson Vaccine and COVID Efficacy Rates

    In today's episode of our news analysis show 16 Minutes, our topic is the ongoing buzz and the mixed news around the Johnson & Johnson vaccine, which was the third vaccine for COVID approved under Emergency Use Authorization by the FDA just a few weeks ago. Johnson & Johnson reported it as “the first single shot vaccine” and as having 85% efficacy in preventing severe disease across regions studied; meanwhile, STAT headlines reported 66% efficacy overall and 72% in the U.S. in preventing moderate to severe disease, calling it “a weapon but not a knockout punch.” And then we have various experts saying everything from “disappointing” to pointing out the dangers of comparing this vaccine to other vaccines such as Pfizer’s and Moderna’s, both of which we’ve talked about on this show. You can find all our ongoing vaccines coverage at a16z.com/vaccines.  

    In this episode — since 16 Minutes is about teasing apart what’s hype/ what’s real in the news and where we are on the long arc of innovation — we asked the a16z bio team for their frameworks. 

    Joining us are General Partner Jorge Conde, who has been in all our vaccine episodes and previously led strategy and product for a  pharmaceuticals company, and bio editorial partner Lauren Richardson, who was previously an editor at PLOS Biology and hosts our sister show Journal Club on Bio Eats World. She also holds a Ph.D in pharmacology.

    • 12 min

Customer Reviews

4.6 out of 5
92 Ratings

92 Ratings

NYC2Europe ,

Fantastic news resource // smart and deep

Please keep it up! Excellent way to keep up with news. Great achievement. Sonol is a total QUEEN!

fndoz ,

Outside of the mainstream, good production

This is a good show. Keep it up!

Top Podcasts In Technology

Listeners Also Subscribed To

More by Andreessen Horowitz